You are here

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Last updated on April 2, 2019

FOR MORE INFORMATION
Study Location
Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA
Rogers, Arkansas, 72758 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Plaque Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months
prior to Baseline/Day 1 (prior to first dose of study drug)

- Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe")
at Baseline/Day 1 (prior to first dose of study drug)

- Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at
Baseline/Day 1 (prior to first dose of study drug)

- Considered by dermatologist investigator to be a candidate for systemic therapy or
phototherapy of psoriasis (either naïve or history of previous treatment)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular
psoriasis, with the exception of nail psoriasis which is allowed

- Have evidence of skin conditions (eg, eczema) at the time of screening or baseline
visit that would interfere with the evaluation of psoriasis

- Cannot discontinue systemic therapies and/or topical therapies for the treatment of
psoriasis and cannot discontinue phototherapy (UVB or PUVA)

- Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).

- Have taken Apremilast (Otezla) within 3 months of first dose of study drug.

- Have undergone treatment with tofacitinib within 3 months of first dose. 

NCT02969018
Pfizer
Completed
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now